TSXV:NDVA.H - Post by User
Post by
Duster340on Aug 17, 2022 10:50am
194 Views
Post# 34902010
Price Target 50 cents
Price Target 50 cents
Echelon Wealth Partners Sticks to Its Buy Rating for Indiva (NDVAF)
Echelon Wealth Partners analyst Andrew Semple reiterated a Buy rating on Indiva (NDVAF – Research Report) yesterday and set a price target of C$0.50. The company’s shares closed yesterday at $0.11.
According to TipRanks, Semple is an analyst with an average return of -1.1% and a 24.50% success rate. Semple covers the Basic Materials sector, focusing on stocks such as Indiva, Vext Science, and Trulieve Cannabis.
Currently, the analyst consensus on Indiva is a Moderate Buy with an average price target of $0.43.
NDVAF market cap is currently $16.98M and has a P/E ratio of -1.37.
Indiva Ltd. engages in the construction of a medical marijuana facility. It offers dried cannabis flower, chocolate, accessories, and oil. The company was founded by Niel Marotta and Koby Smutylo on May 12, 2015 and is headquartered in Ottawa, Canada.